HTG Molecular Diagnostics, Inc. announced that Ann F. Hanham, Ph.D., a director since August 2016, has been appointed to the chair of the company’s board of directors. Dr. Hanham has served for more than 15 years in the life science investment industry as a founding member and managing partner of BAR Capital Management, LLC, and, prior to that, as a managing director and general partner of Burrill & Company. Earlier in her career, Dr. Hanham held positions of increasing responsibility in clinical and regulatory affairs and product development at various companies including InterMune Inc., Otsuka America Pharmaceuticals, Inc., Celtrix Pharmaceuticals, Inc., and Becton Dickinson and Company. She currently serves as a director for two other public companies, and has served on the boards of directors of over 20 companies, both private and public, throughout her distinguished career.